

PATENT
Atty. Docket No. HAR-001DV
(6615/3)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Strominger *et al.*

SERIAL NUMBER: 08/991,628

GROUP NUMBER: 1644

FILING DATE: November 5, 1997

EXAMINER: M. DiBrino

TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS
IMPLICATED IN AUTOIMMUNE DISEASE

RESPONSE TO THE NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES
AND

STATEMENTS UNDER 37 CFR §§ 1.821(f) AND (g)

BOX SEQUENCE
Commissioner for Patents
Washington, D.C. 20231

Sir:

In Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the Patent and Trademark Office on March 8, 2000, a copy of which is attached, we enclose a Sequence Listing in computer-readable form and paper form for the above-referenced divisional application.

AMENDMENTS

Kindly amend the application as follows:

In the Specification:

At page 37, line 11, after the text "X S-", please insert -- (SEQ ID NO: 21) --.

Delete the Sequence Listing of December 16, 1998 and substitute therefor the enclosed pages marked "Sequence Listing".

Applicant: Strominger et al.
U.S.S.N.: 08/991,628
Filed: November 5, 1997
Page 2

STATEMENTS UNDER 37 CFR 1.821(f) AND (g)

The contents of the paper and computer-readable forms of the Sequence Listing are identical. No new matter is introduced by this submission.

REMARKS

The Examiner is invited to call the undersigned with any questions regarding this communication.

Respectfully submitted,



Maureen A. Bresnahan
Attorney for Applicants
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: April 10, 2000
Reg. No. 44,559

Tel. No. (617) 248-7103
Fax: (617) 248-7100

FAIRCHIL6615/3.978124-1



APR 18 2000

GP 1644ND
(BOX Seq)

APR 7 2000

TECH CENTER 1600/2900

PATENT
Attorney Docket No. HAR-001DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Strominger et al.
SERIAL NO.: 08/991,628 GROUP NO.: 1644
FILING DATE: November 5, 1997 EXAMINER: DiBrino, M.
TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS
IMPLICATED IN AUTOIMMUNE DISEASE

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to BOX SEQUENCE, Assistant Commissioner for Patents, Washington, DC 20231, on this 10th day of April, 2000.

April 10, 2000
Date of Signature

Brenda T. Kowalczyk
Brenda T. Kowalczyk

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Submitted herewith are:

Transmittal Form (1 pg.); Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and Statements Under 37 CFR §§ 1.821(f) and (g) (2 pgs.); Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated March 8, 2000 (3 pgs.); Paper copy of Sequence Listing (7 pgs.); computer-readable copy of Sequence Listing on disk (1); a mailroom postcard and this Certificate of First Class Mailing.

BRESNAHA6615/3.978262

TRANSMITTAL FORM



Application Serial Number	08/991,628
Filing Date	November 5, 1997
First Named Inventor	Strominger
Group Art Unit	1644
Examiner Name	DiBrino, M.
Attorney Docket No.	HAR-001DV (6615/3)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> To Convert to a Provisional Application <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund <input type="checkbox"/> After Allowance Communication to Group	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 (1 pg.) <input checked="" type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>) 1. Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and Statements Under 37 CFR §§ 1.821(f) and (g) (2 pgs.) 2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (3 pgs.) 3. Paper copy Sequence Listing (7 pgs.) 4. Computer-readable form on diskette (1)
--	---	---

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK

Date: April 10, 2000
 Reg. No. 44,559
 Tel. No.: (617) 248-7103
 Fax No.: (617) 248-7100

Respectfully submitted,

Maureen A. Bresnahan
 Maureen A. Bresnahan
 Attorney for Applicants
 Testa, Hurwitz & Thibault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office


Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/991,628 11/05/97 STOMINGER

J. HAR-001DV

MICHAEL J TWOMEY
TESTA HURWITZ & THIBEAULT
HIGH STREET TOWER
125 HIGH STREET
BOSTON MA 02210



EXAMINER

DIBRINO, M

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED:

03/08/00

RESPONSE DUE

7.8.00

STATUTORY PERIOD 9.8.00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

RECEIVED

MAR 10 2000 *tlk*


PATENT DEPARTMENT
TESTA, HURWITZ & THIBEAULT, LLP



Washington, D.C. 20231

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.



EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The communication filed on 12/16/98 is not fully responsive to the communication mailed 9/16/98 for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report, i.e., a SEQ ID NO has not been provided for the sequence appearing on page 37 of the instant specification at lines 10-15.


Since the response appears to be **bona fide**, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment.
EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Marianne DiBrino, Art Unit 1644, whose telephone number is 703-308-0061.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 1602

Marianne DiBrino, Ph.D.
February 25, 2000



PR 18 2000

Application No.: 08,991/60

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: A SEQ ID NO has not been provided for the Sequence appearing on page 37 of the instant specification at lines 10-15.

Applicant Must Provide:

- ☒ An ~~initial~~ substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An ~~initial~~ substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

COPY FOR [] File [☒] Applicant